New Hemophilia Database Tracks and Updates Patient Clinical Data in Real Time, Trio Health Announces

New Hemophilia Database Tracks and Updates Patient Clinical Data in Real Time, Trio Health Announces

Trio Health has launched a novel database with real-time clinical data of patients with hemophilia which combines information from medical doctors and pharmacies.

The main aim of the database is to provide information on the treatment regimen to physicians in order to improve patients’ outcomes. Access to the database will be free of charge for all U.S.-based clinical sites.

“It’s important for healthcare practitioners to understand how each patient’s demographics, disease severity, and lifestyle can impact use of particular therapies. With this information, physicians can truly optimize care at the individual patient level, and more clearly understand outcomes,” Brent Clough, Trio Health’s CEO, said in a press release.

The platform includes data from patients with hemophilia A, B, and Von Willebrand disease, which is a common, inherited hemorrhagic disorder resulting from a mutation in the gene that codifies a protein called von Willebrand factor.

The database will include information from 2,000 patients, which correspond to approximately 10 percent of the patients diagnosed with hemophilia in the United States.

“Understanding the use of all factor products by prophylaxis [preventive treatment], episodic, and bleed events provides the framework for delving deeper into identifying the cause, severity, location, days to resolve, and type of bleed, as it relates to the total factor required,” said Clough.

The database, which will be updated every night, uses Trio’s Multi-Disease Platform (MDX) technology to coordinate real-time updates from medical doctors and pharmacies, providing new insights into the treatment outcomes, habits, and financial perspectives of patients.

“With the MDX platform, we have near real-time information that provides a complete understanding of the challenges facing patients with hemophilia; the impact of costs and coverage on prophylactic care, and the burden of frequent administration on patient and caregiver quality of life,” said Scott Milligan, PhD, head of analytics at Trio Health.

“Now that we have deeper insights into the benefits and disadvantages of newer therapies and payer policies, we can identify at-risk populations, and enable changes to maximize outcomes through appropriate care,” Milligan added.

Trio Health, whose goal is to improve quality of care for patients, will also use the real-time hemophilia database to further its insight of patient care patterns and disease management, as well as factor consumption and the influence of payer on treatment measures.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
×
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • Gene therapy
  • SIG-001 orphan drug
  • immune-related genes
  • Atlanta Protocol study

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This